Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, emerging biomarkers and personalized treatment strategies. We begin with an editorial by Isabela Wen-Chi Chang […]

Fred Hirsch, ELCC 2022: Current Unmet needs in Molecular Testing for Patients with Advanced Non-Small Cell Lung Cancer

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: May 5th 2022

Molecular testing is important to selecting patients with advanced non-small cell lung cancer (NSCLC) who may benefit from targeted therapy or immunotherapy. touchONCOLOGY spoke to Professor Fred Hirsch (The Mount Sinai Hospital, New York City, NY, USA) to discuss his presentation at the European Lung Cancer Congress 2022, providing an update on the current state of personalized medicine and molecular testing in lung cancer.

Questions

  1. How well has molecular testing been implemented into clinical practice? 00:24-04:15
  2.  What challenges and unmet needs remain? 04:15-07:20

Speaker Disclosure: Fred Hirsch is a member of the advisory board for: Amgen, AstraZeneca/Daiichi,Bristol-Myers, Novartis, NextCure, Novocure, Nectin Therapeutics, Sanofi/Regeneron and OncoCyteSquibb.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.

Filmed in coverage of the European Lung Cancer Congress 2022

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup